![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Purpose: To evaluate the 6- month daytime efficacy of a fixed combination of timolol and brimonidine (BTFC) versus a timolol and dorzolamide fixed combination (DTFC) as a first choice therapy in patients with pseudoexfoliation glaucoma (PXG).
Methods: This study was a randomized, prospective, investigator-masked, 6-month comparison of twice-daily administration of BTFC versus DTFC in 60 newly diagnosed PXG patients.
Results: Mean baseline untreated IOPs were 25.5 ± 2.6 mmHg and 26.2 ± 2.1 mmHg in the DTFC and BTFC groups, respectively. Mean intraocular pressure (IOP) reductions ranged from −7.3 ± 1.9 to −8.1 ± 2.0 mmHg for the DTFC group and from −7.5 ± 2.0 to −8.6 ± 2.6 mmHg for the BTFC group. No significant differences between the two treatment groups could be found. At month 6, the mean diurnal IOP was 17.5 ± 2.5 mmHg (31.3%) for the DTFC group and 18.0 ± 2.8 mm Hg (31.7%) for BTFC. As compared with baseline, mean diurnal IOP decreased by 7.9 ± 1.9 mmHg in the DTFC and 8.2 ± 1.5mmHg in the BTFC, the difference between the groups was not statistically significant (p = 0.6). No statistical difference in terms of adverse events was found either.
Conclusion: Both fixed combinations were effective at lowering IOP in PXG. This study suggests that the daytime diurnal IOP is not statistically different when DTFC or BTFC is used as a first choice therapy in patients with PXG.
ACKNOWLEDGMENTS
None of the authors has any proprietary interest in any of the drugs or instruments used in the trial. We did not receive any kind of grant or sponsorship to carry out the trial.
Declaration of interest: The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.